scholarly journals In-depth virological assessment of kidney transplant recipients with COVID-19

2020 ◽  
Author(s):  
Ilies Benotmane ◽  
Gabriela Gautier Vargas ◽  
Marie-Josée Wendling ◽  
Peggy Perrin ◽  
Aurélie Velay ◽  
...  
Keyword(s):  
Viral Load ◽  
Kidney Transplant ◽  
Symptom Onset ◽  
Plasma Viral Load ◽  
Humoral Response ◽  
Serological Response ◽  
Upper Respiratory Tract ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Viral Loads

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread widely, causing coronavirus disease 2019 (COVID-19) and significant mortality. However, data on viral loads and antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal and plasma viral loads via RT-PCR and SARS-CoV-2 serology via ELISA and study their association with severe forms of COVID-19 and death in kidney transplant recipients. In this study we examined hospitalized kidney transplant recipients with non-severe (n = 21) and severe (n =19) COVID-19. SARS-CoV-2 nasopharyngeal and plasma viral load and serological response were evaluated based on outcomes and disease severity. Ten recipients (25%) displayed persistent viral shedding 30 days after symptom onset. The SARS-CoV-2 viral load of the upper respiratory tract was not associated with severe COVID-19, whereas the plasma viral load was associated with COVID-19 severity (p=0.0087) and mortality (p=0.024). All patients harbored antibodies the second week after symptom onset that persisted for two months. We conclude that plasma viral load is associated with COVID-19 morbidity and mortality, whereas nasopharyngeal viral load is not. SARS-CoV-2 shedding is prolonged in kidney transplant recipients and the humoral response to SARS-CoV-2 does not show significant impairment in this series of transplant recipients.

scholarly journals Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

2021 ◽  
pp. ASN.2021040490
Author(s):  
Clément Danthu ◽  
Sébastien Hantz ◽  
Arthur Dahlem ◽  
Marion Duval ◽  
Bacary Ba ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Humoral Response ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccination ◽  
Serological Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Medical File ◽  
Hbv Vaccine ◽  
Antibody Titers

Background Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion following vaccination are lower among patients with chronic kidney disease and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. Methods This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36 and 58 days after the first injection. Results In controls, we detected antibodies at a positive level (>13 arbitrary units per milliliter [AU/ml]) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml [IQR, 83.4-526.0]. We detected a positive antibody level in only three transplant recipients at day 36. In hemodialysis patients, those younger than 75 years had a higher antibody response versus those older than 75 years and serum albumin and Kt/V were positively correlated with serological response (P< 0.043 and P<0.019, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers. Conclusions Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients and is reduced by the uremic condition in patients undergoing hemodialysis.

The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis

2018 ◽  
Vol 20 (4) ◽  
pp. e12919 ◽  
Author(s):  
Geovana Basso ◽  
Claudia Rosso Felipe ◽  
Marina Pontello Cristelli ◽  
Juliana Mansur Siliano ◽  
Laila Viana ◽  
...  
Keyword(s):  
Viral Load ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Kinetics Of

scholarly journals Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019

2020 ◽  
Vol 15 (8) ◽  
pp. 1174-1178 ◽  
Author(s):  
S. Ali Husain ◽  
Geoffrey Dube ◽  
Heather Morris ◽  
Hilda Fernandez ◽  
Jae-Hyung Chang ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Clinical Data ◽  
Symptom Onset ◽  
Transplant Recipients ◽  
Outpatient Management ◽  
Kidney Transplant Recipients ◽  
Chi Squared ◽  
Baseline Creatinine ◽  
Early Cohort

Background and objectivesOutcomes of kidney transplant recipients diagnosed with coronavirus disease 2019 as outpatients have not been described.Design, setting, participants, & measurementsWe obtained clinical data for 41 consecutive outpatient kidney transplant recipients with known or suspected coronavirus disease 2019. Chi-squared and Wilcoxon rank sum tests were used to compare characteristics of patients who required hospitalization versus those who did not.ResultsOf 41 patients, 22 (54%) had confirmed coronavirus disease 2019, and 19 (46%) were suspected cases. Patients most commonly reported fever (80%), cough (56%), and dyspnea (39%). At the end of follow-up, 13 patients (32%) required hospitalization a median of 8 days (range, 1–16) after symptom onset, and 23 (56%) had outpatient symptom resolution a median of 12 days (4–23) after onset. Patients who required hospitalization were more likely to have reported dyspnea (77% versus 21%, P=0.003) and had higher baseline creatinine (median, 2.0 versus 1.3 mg/dl, P=0.02), but there were no other differences between groups.ConclusionsIn an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, many had symptomatic resolution without requiring hospitalization.

Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients

2009 ◽  
Vol 9 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Eliana Nogueira ◽  
Kikumi Suzete Ozaki ◽  
Helena Tomiyama ◽  
Niels Olsen Saraiva Câmara ◽  
Celso Francisco Hernandes Granato
Keyword(s):  
Viral Load ◽  
Kidney Transplant ◽  
Human Cytomegalovirus ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Clinical Correlations

scholarly journals Seroprevalence of SARS-CoV-2 IgG Antibodies After the Second BNT162b2 mRNA Vaccine in Japanese Kidney Transplant Recipients

2021 ◽  
Author(s):  
Tomoko Hamaya ◽  
Shingo Hatakeyama ◽  
Tohru Yoneyama ◽  
Yuki Tobisawa ◽  
Hirotake Kodama ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Neutralizing Antibodies ◽  
Humoral Response ◽  
Healthy Controls ◽  
Transplant Recipients ◽  
Igg Antibodies ◽  
Kidney Transplant Recipients ◽  
Univariate Logistic Regression Analysis ◽  
Antibody Titers

Abstract We aimed to evaluate the rate of anti–SARS-CoV-2 IgG seropositivity and investigated factors associated with seropositivity after the second SARS-CoV-2 mRNA vaccination in kidney transplant (KT) recipients. This retrospective study conducted between June 2021 and November 2021 included 106 KT recipients and 127 healthy controls who received the second dose of the BNT162b2 mRNA vaccine at least seven days before the measurement of antibody titers. The titers of immunoglobulin G (IgG) antibodies against the receptor-binding domain of SARS-CoV-2 spike (S) protein were determined. Seropositivity was defined as an anti–SARS-CoV-2 IgG level of ≥15 units/mL, which was considered as the presence of sufficient neutralizing antibodies. The median ages and the seroprevalence rates of the healthy controls and KT recipients were 68 and 56 years and 98% and 22%, respectively. Univariate logistic regression analysis revealed that age >53 years, rituximab use, mycophenolate mofetil use, and KT vintage <7 years were negatively associated with anti–SARS-CoV-2 IgG seropositivity in KT recipients. Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients. Older age, rituximab use, mycophenolate mofetil use, and KT vintage may play key roles in seroconversion.

scholarly journals Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Orly Haskin ◽  
Liat Ashkenazi-Hoffnung ◽  
Noa Ziv ◽  
Yael Borovitz ◽  
Amit Dagan ◽  
...  
Keyword(s):  
Young Adult ◽  
Kidney Transplant ◽  
Adolescent And Young Adult ◽  
Serological Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Adult Kidney

scholarly journals Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients

Vaccine ◽  
2020 ◽  
Vol 38 (17) ◽  
pp. 3339-3350 ◽  
Author(s):  
Simon Oesterreich ◽  
Monika Lindemann ◽  
David Goldblatt ◽  
Peter A. Horn ◽  
Benjamin Wilde ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Real-world Effectiveness of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients

2021 ◽  
Author(s):  
Caitriona M. McEvoy ◽  
Anna Lee ◽  
Paraish S. Misra ◽  
Gerald Lebovic ◽  
Ron Wald ◽  
...  
Keyword(s):  
Cohort Study ◽  
Kidney Transplant ◽  
Real World ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
The Real ◽  
Transplant Program ◽  
The Impact

The humoral response to two doses of SARS-CoV-2 (Covid-19) vaccine among transplant recipients is inferior to immunocompetent individuals. Data on the real-world effectiveness of vaccination in kidney transplant recipients [KTRs] are lacking. We performed a cohort study to investigate the impact of vaccination on Covid-19 infection and outcomes in our kidney transplant program.

Sign in / Sign up

Export Citation Format

Share Document